Egg-allergic patients gain greater access to H1N1 vaccine after completion of clinical trial

Eggertson, Laura
February 2010
CMAJ: Canadian Medical Association Journal;2/9/2010 Supplement, Vol. 182, pE99
Academic Journal
The article reports on the clinical trial completed by Canada's new influenza research network, shows that egg-allergic patients Quebecers have received greater access to the pandemic H1N1 2009 vaccine. It states that the unpublished clinical trial was organized by Dr. Gaston De Serres, a medical epidemiologist. According to Serres, there were two allergic reactions that were treated with Benadryl but were mild dermal reactions.


Related Articles

  • Iota-Carrageenan Is a Potent Inhibitor of Influenza A Virus Infection. Leibbrandt, Andreas; Meier, Christiane; König-Schuster, Marielle; Weinmüllner, Regina; Kalthoff, Donata; Pflugfelder, Bettina; Graf, Philipp; Frank-Gehrke, Britta; Beer, Martin; Fazekas, Tamas; Unger, Hermann; Prieschl-Grassauer, Eva; Grassauer, Andreas // PLoS ONE;2010, Vol. 5 Issue 12, p1 

    The 2009 flu pandemic and the appearance of oseltamivir-resistant H1N1 influenza strains highlight the need for treatment alternatives. One such option is the creation of a protective physical barrier in the nasal cavity. In vitro tests demonstrated that iota-carrageenan is a potent inhibitor of...

  • India Begins Human Clinical Trials for H1N1 Vaccine.  // India -- West;2/12/2010, Vol. 35 Issue 12, pA28 

    The article reports that Serum Institute of India in Pune, India has started clinical trials for its swine flu 2009-H1N1 influenza vaccine after getting permission from the Drugs Controller General of India.

  • Big Drugmakers Start Trials of Swine Flu Vaccines.  // Clinical Infectious Diseases;10/1/2009, Vol. 49 Issue 7, pi 

    The article reports that giant drug manufacturers such as GlaxoSmithKline, Novartis, and Sanofi Aventis have started their clinical trials for the H1N1 swine flu vaccine.

  • Pandemic (H1N1) 2009 lives in some people for at least eight days after symptoms develop.  // CMAJ: Canadian Medical Association Journal;10/27/2009, Vol. 181 Issue 9, pE203 

    The article focuses on the eight-day prolongation of swine flu virus after the development of symptoms as revealed in the research by Dr. Guy Boivin of Centre Hospitalier Universitaire de Quebec and Dr. Gaston De Serres of Quebec's Public Health Institute. The study reveals that majority of the...

  • Chinese herbs for flu treatment. Elliott, William T. // Neurology Alert;Oct2011 Clinical Briefs, p2 

    The article discusses research on H1N1 influenza treatment, referencing a study published in the "Annals of Internal Medicine," which concludes that oseltamivir and Chinese herbs called maxingshigan-yinqiaosan, alone or in combination, decrease time-to-fever resolution in H1N1 influenza patients.

  • Influenza A virus vaccine H1N1.  // Reactions Weekly;10/9/2010, Issue 1322, p18 

    The article describes the cases of two patients, who had a history of an egg allergy and presented with a hypersensitivity reaction after intrasmuscular vaccination with influenza A virus vaccine H1N1, referencing a study published in the January 2010 issue of the "Journal of Allergy and...

  • Only 1 H1N1 Shot Needed, Data from Flu Study Shows. Young, Donna // BioWorld Today;9/14/2009, Vol. 20 Issue 176, p1 

    The article deals with the early results of clinical trials from Australian firm CSL Ltd. and the U.S. National Institute of Allergy and Infectious Diseases (NIAID). According to the study, only one vaccine shot is needed by most healthy adults to protect against the 2009 H1N1 swine flu. The...

  • One or two 7.5-μg doses of MF59-adjuvanted influenza A (H1N1) 2009 vaccine was immunogenic in adults within 21 days. Granwehr, Bruno // ACP Journal Club;1/19/2010, Vol. 152 Issue 1, p7 

    The article discusses a study conducted by doctor I. Stephenson and colleagues to know the immunogenicity and safety of a monovalent MF59-adjuvanted influenza A (H1N1) 2009 vaccine. An interim analysis of a randomized controlled trial of 100 adults between the age 18 to 50 years has found that...

  • Novavax reports positive results from influenza vaccine study.  // PharmaWatch: Biotechnology;May2010, Vol. 9 Issue 5, p8 

    The article reports that biotechnology company Novavax Inc. reports positive results of its two-state pivotal study to evaluate the safety and immunogenicity of its unadjuvanted 2009 A/H1N1 virus-like particle pandemic influenza vaccine. According to the company, data shows that safety and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics